Immunotherapy agent benefits patients with drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators report. —> Read More

facebooktwittergoogle_plusredditpinterestlinkedinmail